Navigation Links
Crescendo Biologics Announces First 'Triple Knockout' Mouse
Date:9/29/2010

mice which retain intact lambda light chain. While lambda light chain accounts for at most 10% of the light chains in mouse antibodies, Crescendo believes that knockout of all light chain expression is critical for the efficient generation of human heavy chain antibodies in transgenic mice. The new knockout mouse thus offers an enhanced background for the generation of new antibody therapeutics and is a key step in the establishment of Crescendo's world-leading VH antibody fragment platform. VH fragments are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics.

In a parallel development, Crescendo has also demonstrated the potential of its first generation yeast artificial chromosome (YAC) with the successful expression of human antibodies. Working with Professor Lluis Montoliu at the Centro Nacional de Biotecnologia (a centre belonging to the Spanish National Research Council, CSIC) in Madrid, transgenic mice have been generated by oocyte microinjection with a first YAC comprising several human V genes, all human D and J genes and a C region engineered for expression in the absence of light chains. This YAC has been shown to rearrange and express human antibodies in wild type mice.

"Today's announcement marks an important milestone in the development of our highly innovative antibody fragment technology," said Mike Romanos, CSO of Crescendo Biologics. "We have successfully delivered what we believe to be a unique asset in our triple knockout mice, and have also made significant steps in the generation of YACs which direct the production of human heavy chain antibodies. When combined, and with further developments in our YAC technology, we believe we will have the strongest platform for the generation of new VH fragment therapeutics and can harness the great benefits they will bring as therapeutics."

The Crescendo approach is aimed at bringing together two highly desirable character
'/>"/>

SOURCE Crescendo Biologics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
2. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
3. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
4. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
5. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
6. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
7. Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
8. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
9. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
10. Dendreon Completes Submission of Biologics License Application for PROVENGE
11. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
(Date:7/31/2014)... , July 31, 2014 According ... Research "Quantum Dots Market - Global Industry Analysis, Size, ... market was valued at USD 88.5 million in 2011, ... 2023, growing at a CAGR of 53.8% from 2013 ... Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand ...
(Date:7/31/2014)... July 31, 2014 Graphite Metallizing Corporation ... temperature oven carts. These bearings are uniquely suited to ... ball bearings because of the high temperatures . ... help from the design engineers at Graphite Metallizing to ... process. During their manufacturing operation, pans containing blocks of ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3
... Nile Therapeutics,Inc. (OTC Bulletin Board: NILT.OB), a ... today announced the,appointment of Gregory W. Schafer to ... audit committee. Mr. Schafer is a seasoned biotechnology ... finance and operations., "We are delighted to ...
... Lentigen Corporation today announced,the appointment of Tim Ravenscroft ... chairman, commented, "The board of Lentigen,is delighted that ... are about to enter,clinical trials for our first ... particularly strong background and global leadership in,healthcare products ...
... Arno Therapeutics, Inc., a,privately held drug development ... license agreements with The Ohio State University,("OSU") for ... therapies for cancer., Pursuant to the license ... for the treatment of cancer, including OSU-03012 (NSC,D728209) ...
Cached Biology Technology:Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 3Lentigen Appoints Tim Ravenscroft as Chief Executive Officer 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... most diverse families in the ocean today -- marine ... more than 400 million years ago in the Silurian ... its modern members. This Geology study by ... on 25 July 2014, tracks the remarkable evolutionary expansion ... is origin, the Lucinidae family remained at very low ...
(Date:8/1/2014)... co-authors of a new study, including two Simon ... scientists, industry representatives and policymakers must collaborate closely ... shale gas development. Viorel Popescu and Maureen Ryan, ... Biological Sciences department, are among eight international co-authors ... in Ecology and the Environment . , Shale ...
Breaking Biology News(10 mins):A map for eye disease 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3
... Colorado and TUSTIN, Calif., April 21, 2009--Peregrine ... biopharmaceutical company developing monoclonal antibodies for the ... today reported that two preclinical studies presented ... provided further confirmation of the immunomodulatory mechanisms ...
... 50 years as one of the most effective treatments ... been entirely sure exactly how it operates in the ... scientists suggests a mechanism for how Lithium works, opening ... tests on cells have shown that Lithium affects a ...
... MEDFORD/SOMERVILLE, Mass. -- A collaborative team of student designers, ... and Tufts University will use Earth Day as an ... a house that will be solar powered, attractive and ... April 22, at 11:00 a.m. at Sophia Gordon Hall ...
Cached Biology News:Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 2Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 3Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies 4Tufts students host Earth Day with groundbreaking ceremony for solar house 2Tufts students host Earth Day with groundbreaking ceremony for solar house 3
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
Biology Products: